We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

RF Ablation Successful in Treating Inoperable Lung Cancer

By HospiMedica staff writers
Posted on 09 Apr 2007
A minimally invasive procedure known as radiofrequency (RF) ablation is effective for treating lung cancer in patients who are not candidates for surgery, according to a recent study.

Damian Dupuy, M.D., director of ablation at Rhode Island Hospital (Providence, RI, USA) and professor of diagnostic imaging at the Warren Alpert Medical School of Brown University (Providence, RI, USA), conducted a study of 153 patients who were treated for early-stage, inoperable lung cancer with RF ablation. More...
The procedure involves using a specialized needle inserted through the skin to transmit high-frequency electrical currents into a tumor.

The overall findings of the study revealed RF ablation safe and tied it to promising long-term survival and local tumor progression outcomes when compared to the older treatment method of external beam radiation (EBT).
EBT, which has been used for decades, requires many treatments over a six-week period. This can frequently lead to a variety of side effects. RF ablation, however, is performed in a single day on an outpatient basis, is minimally invasive and has few side effects.

"Our study has shown that this minimally invasive procedure can successfully treat patients with lung cancer who could not undergo surgery in one fairly simple treatment. The study also shows that radiofrequency ablation is equal to or more effective in terms of both survival and tumor control,” commented Dr. Dupuy. With RF ablation, the Rhode Island Hospital researchers noted a two-year survival rate at 57% compared to 51% using EBT.
"With lung cancer screening for at-risk individuals on the horizon, we will be able to detect lung cancers at earlier stages. In my lifetime, I foresee image-guided radiofrequency ablation replacing many surgical procedures for the treatment of cancer as we continue to improve these minimally invasive treatment methods,” stated Dr. Dupuy.

Other survival rates for stage I, non-small cell cancer treated with RF ablation were 78% for one year, 57% for two years, 36% for three years, and 27% for both four and five years.

The study was published in the April 2007 issue of the journal Radiology.


Related Links:
Brown University

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Pediatric Mask
Respire SOFT
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.